Beigene LtdNASDAQ:BGNE
- LAST PRICE191.3200
- TODAY'S CHANGE (%)-0.2600 (-0.1357%)
- Bid / Lots175.0000/ 1
- Ask / Lots198.7900/ 1
- Open / Previous Close192.8100 / 191.5800
- Day Range
- 52 Week Range
- Volume136,979
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BGNE |
|---|---|---|
| 09:32 ET | 3099 | 192.9 |
| 09:39 ET | 400 | 193.035 |
| 09:41 ET | 100 | 192.28 |
| 09:50 ET | 100 | 191.4 |
| 09:52 ET | 109 | 191.3779 |
| 09:56 ET | 566 | 190.9361 |
| 09:57 ET | 100 | 190.97 |
| 09:59 ET | 100 | 191.695 |
| 10:03 ET | 200 | 190.78 |
| 10:06 ET | 200 | 190.6 |
| 10:08 ET | 234 | 190.38 |
| 10:10 ET | 684 | 190.47 |
| 10:12 ET | 26200 | 190.46 |
| 10:14 ET | 100 | 191.12 |
| 10:15 ET | 200 | 190.715 |
| 10:17 ET | 100 | 190.66 |
| 10:19 ET | 100 | 190.08 |
| 10:21 ET | 193 | 190.51 |
| 10:24 ET | 200 | 190.58 |
| 10:26 ET | 200 | 190.9 |
| 10:28 ET | 190 | 191.18 |
| 10:30 ET | 300 | 191.15 |
| 10:32 ET | 300 | 191.095 |
| 10:33 ET | 200 | 191.27 |
| 10:35 ET | 900 | 190.23 |
| 10:37 ET | 408 | 189.9 |
| 10:46 ET | 300 | 189.54 |
| 10:51 ET | 100 | 189.31 |
| 10:57 ET | 600 | 189.265 |
| 11:00 ET | 200 | 188.86 |
| 11:02 ET | 200 | 189.32 |
| 11:09 ET | 300 | 189.15 |
| 11:15 ET | 272 | 189.105 |
| 11:24 ET | 295 | 189 |
| 11:26 ET | 2800 | 188.66 |
| 11:27 ET | 1027 | 188.61 |
| 11:38 ET | 1200 | 188.79 |
| 11:42 ET | 100 | 189.075 |
| 11:45 ET | 200 | 188.87 |
| 11:47 ET | 200 | 188.855 |
| 11:51 ET | 1200 | 188.61 |
| 11:56 ET | 100 | 188.75 |
| 11:58 ET | 100 | 188.99 |
| 12:00 ET | 300 | 189.11 |
| 12:02 ET | 400 | 188.79 |
| 12:03 ET | 200 | 188.92 |
| 12:09 ET | 700 | 189.065 |
| 12:12 ET | 200 | 189.14 |
| 12:21 ET | 100 | 189.28 |
| 12:30 ET | 400 | 189.235 |
| 12:39 ET | 100 | 189.4 |
| 12:41 ET | 100 | 189.55 |
| 12:50 ET | 300 | 189.53 |
| 12:52 ET | 462 | 189.3654 |
| 12:56 ET | 100 | 189.3 |
| 12:57 ET | 100 | 189.51 |
| 01:03 ET | 388 | 189.4004 |
| 01:10 ET | 600 | 190.385 |
| 01:14 ET | 100 | 190.605 |
| 01:15 ET | 109 | 190.64 |
| 01:17 ET | 300 | 191.2 |
| 01:19 ET | 100 | 191.01 |
| 01:21 ET | 200 | 191.36 |
| 01:24 ET | 100 | 191.38 |
| 01:30 ET | 200 | 191.285 |
| 01:33 ET | 100 | 191.56 |
| 01:37 ET | 100 | 191.59 |
| 01:42 ET | 100 | 191.57 |
| 01:44 ET | 218 | 191.29 |
| 01:46 ET | 649 | 191.715 |
| 01:48 ET | 200 | 191.74 |
| 01:50 ET | 100 | 191.84 |
| 01:53 ET | 600 | 191.8 |
| 01:55 ET | 2280 | 192.54 |
| 02:00 ET | 200 | 192.375 |
| 02:02 ET | 100 | 192.59 |
| 02:04 ET | 800 | 192.215 |
| 02:06 ET | 100 | 191.93 |
| 02:08 ET | 300 | 192.04 |
| 02:20 ET | 300 | 192.415 |
| 02:26 ET | 200 | 192.105 |
| 02:36 ET | 961 | 191.675 |
| 02:42 ET | 400 | 191.77 |
| 02:45 ET | 132 | 191.7507 |
| 02:49 ET | 200 | 191.94 |
| 02:56 ET | 100 | 191.95 |
| 02:58 ET | 400 | 191.92 |
| 03:02 ET | 200 | 191.895 |
| 03:07 ET | 100 | 191.99 |
| 03:12 ET | 483 | 191.88 |
| 03:14 ET | 100 | 192.11 |
| 03:16 ET | 100 | 192.04 |
| 03:20 ET | 600 | 191.83 |
| 03:21 ET | 200 | 191.885 |
| 03:27 ET | 100 | 192.115 |
| 03:30 ET | 100 | 192.34 |
| 03:34 ET | 200 | 192.1 |
| 03:36 ET | 100 | 192.075 |
| 03:38 ET | 656 | 192.01 |
| 03:39 ET | 400 | 191.85 |
| 03:41 ET | 200 | 191.73 |
| 03:43 ET | 100 | 191.9 |
| 03:45 ET | 1703 | 191.81 |
| 03:48 ET | 456 | 191.88 |
| 03:50 ET | 100 | 192.035 |
| 03:52 ET | 1100 | 191.95 |
| 03:54 ET | 1008 | 191.68 |
| 03:56 ET | 2401 | 191.76 |
| 03:57 ET | 200 | 191.86 |
| 03:59 ET | 15491 | 191.32 |
Aug 28, 2024
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference, from 6:01AM ET on Wednesday Aug 28, 2024 by Dow Jones
6:01AM ET on Wednesday Aug 28, 2024 by Dow Jones
Aug 26, 2024
BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL, from 6:00AM ET on Monday Aug 26, 2024 by Dow Jones
6:00AM ET on Monday Aug 26, 2024 by Dow Jones
Aug 20, 2024
DJ BeiGene Is Maintained at Overweight by JP Morgan, from 10:23AM ET on Tuesday Aug 20, 2024 by Dow Jones
10:23AM ET on Tuesday Aug 20, 2024 by Dow Jones
Aug 8, 2024
DJ BeiGene Is Maintained at Buy by Citigroup, from 3:22PM ET on Thursday Aug 08, 2024 by Dow Jones
3:22PM ET on Thursday Aug 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beigene Ltd | 21.0B | -37.7x | --- |
Biomarin Pharmaceutical Inc | 16.0B | 63.4x | --- |
United Therapeutics Corp | 15.4B | 15.9x | +8.22% |
Exact Sciences Corp | 10.9B | -61.5x | --- |
Neurocrine Biosciences Inc | 12.1B | 36.3x | +62.04% |
Qiagen NV | 10.0B | 139.8x | +12.66% |
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Contact Information
- Headquarters
- C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
- Phone
- 345-949-4123
- Fax
- ---
Executives
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- John Oyler
- President, Chief Operating Officer, General Manager - China
- Xiaobin Wu
- Co-Founder, Non-Executive Director
- Xiaodong Wang
- Chief Financial Officer
- Aaron Rosenberg
- Senior Vice President, General Counsel
- Chan Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.0B |
|---|---|
Revenue (TTM) | $3.1B |
Shares Outstanding | 106.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-5.08 |
Book Value | $36.95 |
P/E Ratio | -37.7x |
Price/Sales (TTM) | 6.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
